{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:56:19Z","timestamp":1773924979633,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T00:00:00Z","timestamp":1513555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T00:00:00Z","timestamp":1513555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1038\/s41409-017-0033-0","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T19:11:03Z","timestamp":1513105863000},"page":"246-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Plerixafor in poor mobilizers with non-Hodgkin\u2019s lymphoma: a multi-center time-motion analysis"],"prefix":"10.1038","volume":"53","author":[{"given":"Mohamad","family":"Mohty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabih","family":"Azar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3755-4889","authenticated-orcid":false,"given":"Christian","family":"Chabannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Milkovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Ostermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Gla\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Noppeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Kron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"H\u00fcbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,18]]},"reference":[{"key":"33_CR1","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.transci.2013.07.025","volume":"49","author":"L Pierelli","year":"2013","unstructured":"Pierelli L, Berto P, Accorsi P, Milone G, Lopatriello S, Aiello A, et al. The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: Results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Societ\u00e0 Italiana di Emaferesi e Manipolazione Cellulare. Transfus Apher Sci. 2013;49:615\u201322.","journal-title":"Transfus Apher Sci"},{"key":"33_CR2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00277-012-1530-2","volume":"91","author":"HM Blommestein","year":"2012","unstructured":"Blommestein HM, Verelst SGR, Huijgens PC, Blijlevens NMA, Cornelissen JJ, Uyl-De Groot CA. Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Ann Hematol. 2012;91:1945\u201352.","journal-title":"Ann Hematol"},{"key":"33_CR3","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1038\/bmt.2009.370","volume":"45","author":"MA Gertz","year":"2010","unstructured":"Gertz MA, Wolf RC, Micallef INM, Gastineau Da. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transpl. 2010;45:1396\u2013403.","journal-title":"Bone Marrow Transpl"},{"key":"33_CR4","doi-asserted-by":"crossref","unstructured":"Chabannon C, Le Corroller A-G, Viret D, Eillen C, Faucher C, Moatti J-P, et al. Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation [4]. Leukemia 2003;17:811\u20133.","DOI":"10.1038\/sj.leu.2402867"},{"key":"33_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/bmt.2014.39","volume":"49","author":"M Mohty","year":"2014","unstructured":"Mohty M, H\u00fcbel K, Kr\u00f6ger N, Aljurf M, Apperley J, Basak GW, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2014;49:865\u201372.","journal-title":"Bone Marrow Transpl"},{"key":"33_CR6","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.bbmt.2010.11.021","volume":"17","author":"PJ Stiff","year":"2011","unstructured":"Stiff PJ, Micallef I, Nademanee AP, Stadtmauer EA, Maziarz RT, Bolwell BJ, et al. Transplanted CD34+ cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transpl. 2011;17:1146\u201353.","journal-title":"Biol Blood Marrow Transpl"},{"key":"33_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1083-8791(03)00232-5","volume":"9","author":"N Gunn","year":"2003","unstructured":"Gunn N, Damon L, Varosy P, Navarro W, Martin T, Ries C, et al. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transpl. 2003;9:643\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"33_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","volume":"20","author":"S Giralt","year":"2014","unstructured":"Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transpl. 2014;20:295\u2013308.","journal-title":"Biol Blood Marrow Transpl"},{"key":"33_CR9","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1200\/JCO.1999.17.4.1227","volume":"17","author":"KA Schulman","year":"1999","unstructured":"Schulman KA, Birch R, Zhen B, Pania N, Weaver CH. Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. J Clin Oncol. 1999;17:1227\u201333.","journal-title":"J Clin Oncol"},{"key":"33_CR10","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.bbmt.2009.06.018","volume":"15","author":"CT Wallington-Beddoe","year":"2009","unstructured":"Wallington-Beddoe CT, Gottlieb DJ, Garvin F, Antonenas V, Sartor MM. Failure to achieve a threshold bose of CD34+ CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transpl. 2009;15:1386\u201393.","journal-title":"Biol Blood Marrow Transpl"},{"key":"33_CR11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/sj.bmt.1705298","volume":"37","author":"V Pavone","year":"2006","unstructured":"Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006;37:719\u201324.","journal-title":"Bone Marrow Transplant"},{"key":"33_CR12","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","volume":"14","author":"I Pusic","year":"2008","unstructured":"Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transpl. 2008;14:1045\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"key":"33_CR13","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.bbmt.2009.08.005","volume":"15","author":"IN Micallef","year":"2009","unstructured":"Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Bridger G, et al. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transpl. 2009;15:1578\u201386.","journal-title":"Biol Blood Marrow Transpl"},{"key":"33_CR14","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009;27:4767\u201373.","journal-title":"J Clin Oncol"},{"key":"33_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/sj.bmt.1705908","volume":"41","author":"G Calandra","year":"2008","unstructured":"Calandra G, McCarty J, McGuirk J, Tricot G, Crocker S, Badel K, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin\u2019s lymphoma, Hodgkin\u2019s disease and multiple myeloma patients previously failing mobilization with chemotherapy and\/or cytokine treatment: compassionate use data. Bone Marrow Transpl. 2008;41:331\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"33_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/bmt.2010.54","volume":"46","author":"RF Duarte","year":"2011","unstructured":"Duarte RF, Shaw BE, Mar\u00edn P, Kottaridis P, Ortiz M, Morante C, et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transpl. 2011;46:52\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"33_CR17","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1111\/trf.13141","volume":"55","author":"C Chabannon","year":"2015","unstructured":"Chabannon C, Bijou F, Miclea JM, Milpied N, Grouin JM, Mohty M. A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the \u201con-demand\u201d scheme of administration at French autologous hematopoietic stem cell transplant programs. Transfusion. 2015;55:2149\u201357.","journal-title":"Transfusion"},{"key":"33_CR18","doi-asserted-by":"crossref","unstructured":"Azar N, Ouzegdouh M, Choquet S, Leblond V. Impact of Plerixafor (Mozobil) on hospital efficiency: a single center experience. J Clin Apher. 2017;Apr 28(Epub ahead of print).","DOI":"10.1002\/jca.21551"},{"key":"33_CR19","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1089\/15258160050196812","volume":"9","author":"KR Meehan","year":"2000","unstructured":"Meehan KR, Areman EM, Ericson SG, Matias C, Seifeldin R, Schulman K. Mobilization, collection, and processing of autologous peripheral blood stem cells: development of a clinical process with associated costs. J Hematother Stem Cell Res. 2000;9:767\u201371.","journal-title":"J Hematother Stem Cell Res"},{"key":"33_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00019053-200927010-00006","volume":"27","author":"P Fagnoni","year":"2009","unstructured":"Fagnoni P, Milpied N, Limat S, Deconinck E, Nerich V, Foussard C, et al. Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin\u2019s lymphoma. Pharmacoeconomics. 2009;27:55\u201368.","journal-title":"Pharmacoeconomics"},{"key":"33_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbmt.2012.08.010","volume":"19","author":"INM Micallef","year":"2012","unstructured":"Micallef INM, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transpl. 2012;19:87\u201393.","journal-title":"Biol Blood Marrow Transpl"},{"key":"33_CR22","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.bbmt.2013.05.008","volume":"19","author":"P Shaughnessy","year":"2013","unstructured":"Shaughnessy P, Chao N, Shapiro J, Walters K, McCarty J, Abhyankar S, et al. Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature. Biol Blood Marrow Transpl. 2013;19:1301\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"33_CR23","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.bbmt.2012.05.017","volume":"18","author":"AP Nademanee","year":"2012","unstructured":"Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, et al. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of. Biol Blood Marrow Transpl. 2012;18:1564\u201372.","journal-title":"Biol Blood Marrow Transpl"},{"key":"33_CR24","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1111\/j.1537-2995.2011.03136.x","volume":"51","author":"J Li","year":"2011","unstructured":"Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, et al. Effectiveness and cost analysis of \u201cjust-in-time\u201d salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion. 2011;51:2175\u201382.","journal-title":"Transfusion"},{"key":"33_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/jca.21256","volume":"28","author":"GA Abusin","year":"2013","unstructured":"Abusin GA, Abu-Arja RF, Gingrich RD, Silverman MD, Zamba GKD, Schlueter AJ. An algorithm for utilizing peripheral blood CD34 count as a predictor of the need for plerixafor in autologous stem cell mobilization--cost-effectiveness analysis. J Clin Apher. 2013;28:293\u2013300.","journal-title":"J Clin Apher"},{"key":"33_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/jca.21433","volume":"31","author":"A Martin","year":"2016","unstructured":"Martin A, Richards S, Haycox A, Houten R, McLeod C, Braithwaite B, et al. Evaluating the use of plerixafor in stem cell mobilisation\u2014an economic analysis of the PHANTASTIC trial. J Clin Apher. 2016;31:434\u201342.","journal-title":"J Clin Apher"},{"key":"33_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1537-2995.2011.03206.x","volume":"52","author":"P Vishnu","year":"2012","unstructured":"Vishnu P, Roy V, Paulsen A, Zubair AC. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion. 2012;52:55\u201362.","journal-title":"Transfusion"},{"key":"33_CR28","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/j.jcyt.2014.05.003","volume":"16","author":"SS Kim","year":"2014","unstructured":"Kim SS, Renteria AS, Steinberg A, Banoff K, Isola L. Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma. Cytotherapy. 2014;16:1584\u20139.","journal-title":"Cytotherapy"},{"key":"33_CR29","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/trf.12434","volume":"54","author":"V Varmavuo","year":"2014","unstructured":"Varmavuo V, Rimpil\u00e4inen J, Kuitunen H, Nihtinen A, Vasala K, Mikkola M, et al. Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin\u2019s lymphoma patients. Transfusion. 2014;54:1243\u201350.","journal-title":"Transfusion"},{"key":"33_CR30","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/sj.bmt.1704988","volume":"35","author":"V Mishra","year":"2005","unstructured":"Mishra V, Andresen S, Brinch L, Kval\u00f8y S, Ernst P, L\u00f8nset MK, et al. Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transpl. 2005;35:1149\u201353.","journal-title":"Bone Marrow Transpl"},{"key":"33_CR31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/sj.bmt.1703729","volume":"30","author":"C Tarella","year":"2002","unstructured":"Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omed\u00e8 P, et al. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transpl. 2002;30:725\u201332.","journal-title":"Bone Marrow Transpl"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-017-0033-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-017-0033-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-017-0033-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T22:20:17Z","timestamp":1630621217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-017-0033-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,18]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["33"],"URL":"https:\/\/doi.org\/10.1038\/s41409-017-0033-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,18]]},"assertion":[{"value":"28 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MM received research support, honorarium and hospitality from SANOFI SA NA received honorarium, consultancies to sponsoring organizations and hospitality from SANOFI SA CC received research support, honorarium and hospitality from SANOFI SA and Honorarium from Terumo BCT. L.K. received traveling and accommodation support from SANOFI for ASH meeting 2015. HO received research support from SANOFI SA BG received honoraria and research funding from Sanofi and Amgen. KH received honorarium and hospitality from SANOFI SA The authors have no commercial, proprietary or financial interest in the products or companies described in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}